Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 1st International Workshop on GPRC5D-targeted myeloma therapies (iwGPRC5D) took place in New York City, NY, on 21-22 March 2025. This workshop brought together leading clinical and translational researchers to discuss the latest advances in GPRC5D-targeted therapies for multiple myeloma. iwGPRC5D was supported by Johnson&Johnson. Supporters have no influence over the production of the content.
iwGPRC5D 2025
International Workshop on GPRC5D-targeted myeloma therapies
21–22 March 2025 | New York, NY
The 1st International Workshop on GPRC5D-targeted myeloma therapies (iwGPRC5D) took place in New York City, NY, on 21-22 March 2025. This workshop brought together leading clinical and translational researchers to discuss the latest advances in GPRC5D-targeted therapies for multiple myeloma. iwGPRC5D was supported by Johnson&Johnson. Supporters have no influence over the production of the content.
Session 1: Basic/pre-clinical
GPRC5D: pioneering a novel target for immunotherapy – from discovery to translation
Eric Smith Dana-Farber Cancer Institute, Boston, MA, United States
Session 2: Translational
The role of the microbiome in myeloma disease progression
Annamaria Ballweg Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Predictors of response and resistance to talquetamab
Tarek Mouhieddine Mount Sinai Medical Center, New York City, NY, United States
Genomic determinants of resistance to GPRC5D therapies
Francesco Maura Memorial Sloan Kettering Cancer Center, New York, NY, United States
Session 3: Clinical updates
Clinical update on GPRC5D-directed CAR T-cells in R/R multiple myeloma
Susan Bal University of Alabama, Birmingham, AL, United States
GPRC5D-directed bispecific antibodies
Shonali Midha Dana-Farber Cancer Institute, Boston, MA, United States
GPRC5D antibody-drug conjugates
Sridevi Rajeeve Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Content coming soon
Bispecific antibody delivery in older/frailer patients
Charlotte Pawlyn The Institute of Cancer Research, London, United Kingdom
Session 4: Practical aspects of GPRC5D therapies (part I)
Infection risk with BCMA and GPRC5D therapies
Tomáš Jelínek University of Ostrava, Ostrava, Czech Republic
Oral and GI toxicities associated with GPRC5D therapies
Andrew Yee Massachusetts General Hospital, Boston, MA, United States
Skin toxicities associated with GPRC5D therapies: time to make rash decisions
Rahul Banerjee Fred Hutchinson Cancer Center, Seattle, WA, United States
Management of GPRC5D-related toxicities
Joshua Richter Mount Sinai Medical Center, NY, United States
Session 5: Practical aspects of GPRC5D therapies (part II)
Optimal sequencing of BCMA and GPRC5D therapies
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
Real-world outcomes with talquetamab
Hamza Hashmi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
A German multicenter real-world analysis of talquetamab in 138 patients with R/R multiple myeloma
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
